TX-FLUENCE
29.2.2024 14:31:32 CET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its newest LED top light solutions for produce and ornamental cultivators: RAPTR 2 and VYPR 4.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229846318/en/
Fluence announced its newest LED top light solutions for produce and ornamental cultivators: RAPTR 2 and VYPR 4. (Photo: Business Wire)
Fluence’s latest LED innovations were developed in parallel with the company’s global research program, which includes partnerships with industry leaders worldwide and in-house analysis of spectral optimization across crops. The new RAPTR and VYPR offerings build upon Fluence’s existing portfolio of lighting solutions to offer robust fixtures with higher wattages, greater efficiencies and overall increased ROI for growers throughout the world.
RAPTR 2: Higher wattages and tunable spectra help growers maximize light output and efficiency at lower installation costs
The RAPTR 2 fixture’s wide power range (up to 1400 W), multi-channel tunable spectra and up to 5050 μmol/s of light output make it the optimal lighting solution for upgrading HPS fixtures in greenhouse environments. Featuring steerable spectra—including far red—integrated wireless dimming capability and efficacies up to 4.0 μmol/J, cultivators can achieve improved crop performance and lower operating expenses with the new RAPTR 2.
“The latest RAPTR and VYPR series luminaires showcase that Fluence’s primary mission remains unchanged: Help the world grow smarter through the most advanced LED fixtures,” said Steve Graves, senior vice president of strategy and business development at Fluence. “We're excited to launch our most powerful and efficient solutions yet and we look forward to advancing the industry together with partners across the globe.”
VYPR 4: More versatility and control that maximizes cultivation results
Featuring the VYPR line’s familiar low-profile design, VYPR 4 offers more spectral options, light uniformity at any mounting height, easy installation and higher light intensities with lower energy consumption.
“VYPR 4 is a versatile top light solution,” said Jordon Musser, chief product officer for Fluence. “The latest generation focuses on what every grower wants: a more efficient output that yields a clear ROI. Installation is swift, the fixtures are extremely durable, and growers can tap into Fluence’s diverse spectral options to curate a lighting program unique to their cultivation goals.”
VYPR 4 features output up to 3030 μmol/s and efficiency up to 3.9 μmol/J. The fixture also includes dual-channel far red spectra as well as Fluence’s wide variety of PhysioSpec™ spectra to empower growers with multiple lighting strategies. VYPR 4’s low profile creates the least possible shading in a greenhouse environment and now offers a wide-beam optic for optimized light distribution.
Fluence will showcase RAPTR 2 and VYPR 4 during its upcoming global trade shows, including HortiContact from March 5 to March 7, 2024 in the Netherlands.
To learn more about the RAPTR and VYPR series and how to schedule a trial at your facility, visit www.fluence-led.com.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis, produce and flower markets, committed to enabling more efficient crop production for the world’s top greenhouse and indoor growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Professional Business. For more information about Fluence, visit www.fluence-led.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229846318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom